Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
26 Aprile 2024 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat and prevent within
the field of hearing loss disorders, today announces its
participation in the 27th Annual American Society of Cell and Gene
Therapy Meeting (ASGCT), taking place on May 7-11, 2024, in
Baltimore, United States of America.
On this occasion, Rafik Boudra, Group Leader Technology &
innovation Platform at Sensorion, will present the following poster
on May 10, 2024, at 12pm ET, in the Exhibit Hall:
Preclinical Development of SENS-501 as a Treatment for the
Autosomal Recessive Non-Syndromic Deafness 9 (DFNB9) Using an Adeno
Associated Vector-Based Gene Therapy (abstract number:
1476)
An abstract of the poster can be found here.
The poster will be displayed up to 7pm ET this same day.
About Sensorion Sensorion is a pioneering clinical-stage
biotech company, which specializes in the development of novel
therapies to restore, treat, and prevent hearing loss disorders, a
significant global unmet medical need. Sensorion has built a unique
R&D technology platform to expand its understanding of the
pathophysiology and etiology of inner ear related diseases,
enabling it to select the best targets and mechanisms of action for
drug candidates. It has two gene therapy programs aimed at
correcting hereditary monogenic forms of deafness, developed in the
framework of its broad strategic collaboration focused on the
genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT)
currently being developed in a Phase 1/2 clinical trial, targets
deafness caused by mutations of the gene encoding for otoferlin and
GJB2-GT targets hearing loss related to mutations in GJB2 gene to
potentially address important hearing loss segments in adults and
children. The Company is also working on the identification of
biomarkers to improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small molecule
programs for the treatment and prevention of hearing loss
disorders. Sensorion’s clinical-stage portfolio includes one Phase
2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2
proof of concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022. www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer This press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the 2023 full year report published on March 14, 2024,
and available on our website and to the development of economic
conditions, financial markets and the markets in which Sensorion
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Sensorion or not
currently considered material by Sensorion. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Sensorion to be
materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425656204/en/
Investor Relations Noémie Djokovic, Chargée des Relations
Investisseurs et de la Communication
ir.contact@sensorion-pharma.com
Press Relations Ulysse Communication Bruno Arabian / 00
00(0)6 87 88 47 26 barabian@ulysse-communication.com Nicolas Entz /
00 33 (0)6 33 67 31 54 nentz@ulysse-communication.com
Grafico Azioni Sensorion (EU:ALSEN)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Sensorion (EU:ALSEN)
Storico
Da Gen 2024 a Gen 2025
